Tired of slow and inaccurate aspergillosis diagnostics? acib’s innovative DNA aptamer technology revolutionizes diagnostics with precision and speed.
Background
Aspergillosis, a life-threatening infection caused by Aspergillus species, poses a significant health risk, especially to immunocompromised individuals. This fungal disease affects millions annually while limitations
in diagnosis often delay treatment, exacerbating the mortality rate:
- Time-consuming: Traditional methods, such as culturing are slow, often delaying crucial early diagnosis.
- Low sensitivity and specificity: Many tests fail to detect early-stage infections or distinguish between Aspergillus species, hindering targeted treatment.
- Complex procedures: Existing diagnostics require specialized equipment, restricting their use in resource-limited settings.
Technology
acib has developed a groundbreaking diagnostic tool based on DNA aptamers. Aptamers are short, single-stranded synthetic DNA molecules that can specifically bind to target molecules such as proteins, toxins, or fungal cells. Their unique 3D structure allows for high
specificity in target binding, making them ideal for diagnostics. acib‘s aptamer-based platform detects Aspergillus infections with:
- Improved sensitivity: Aptamer-based assays can potentially detect even low levels of Aspergillus cells, facilitating earlydiagnosis.
- Enhanced specificity: By targeting unique Aspergillus antigens, aptamers can differentiate between Aspergillus species, guiding appropriate treatment.
- Simplified procedures: Aptamer-based tests can be designed for point-of-care applications, requiring minimal laboratory equipmentor expertise.
Offer
acib’s innovative diagnostic platform has the potential to transform fungal disease detection and save lives by offering fast, specific, and cost-effective diagnostics. We are actively seeking industry partners for joint projects to help bring this game-changing technology to market. Partners can gain exclusive rights to the IP developed in such a project, positioning them at the forefront of a new era in fungal diagnostics.
Experts:
Prof. Dr. Matthias Steiger, Dr. Valerie EllenaDevelopment status:
Technology Readiness Level 2 (technology concept formulated)Keywords:
Rapid Diagnostic Tests, Species-specific detection, Molecular Diagnostics, Invasisve Aspergillosis, Pulmonary Aspergillosis, R&D Partnership, Biomarkers, Healthcare Technology, Point-of-Care Diagnostics, Commercialization
